scholarly journals Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer

JGH Open ◽  
2021 ◽  
Author(s):  
Kenji Ikezawa ◽  
Ryosuke Kiyota ◽  
Ryoji Takada ◽  
Kazuma Daiku ◽  
Shingo Maeda ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Metastatic Pancreatic Cancer ◽  
Second Line ◽  
Efficacy And Safety ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Aziz Zaanan ◽  
Isabelle Trouilloud ◽  
Theofano Markoutsaki ◽  
Mélanie Gauthier ◽  
Anne-Claire Dupont-Gossart ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Metastatic Pancreatic Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Efficacy of S-1 compared to modified FOLFIRINOX as second-line chemotherapy regimens after gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 449-449 ◽  
Author(s):  
Gen Kimura ◽  
Hideaki Takahashi ◽  
Kumiko Umemoto ◽  
Kazuo Watanabe ◽  
Mitsuhito Sasaki ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Chemotherapy Regimen ◽  
Phase Iii ◽  
Metastatic Pancreatic Cancer ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Second Line Chemotherapy ◽  
Clinical Records ◽  
Line Chemotherapy

449 Background: Recently, gemcitabine (GEM) plus nab-paclitaxel (nab-PTX) has been frequently used as a first-line chemotherapy regimen for the treatment of metastatic pancreatic cancer (mPC) in Japan. Nanoliposomal irinotecan combined with 5-fluorouracil and leucovorin (MM-398 plus 5FU/LV) has not yet been approved in Japan. Under these circumstances, a modified FOLFIRINOX (mFFX) regimen or S-1 is commonly used as a second-line chemotherapy regimen for patients with mPC after GEM plus nab-PTX has failed. Methods: Between December 2014 and March 2016, 45 patients with mPC received second-line chemotherapy after the failure of GEM plus nab-PTX (standard dose regimen) at the National Cancer Center Hospital East. Twenty-two patients received mFFX (irinotecan, 150 mg/m2; bolus of 5FU was eliminated), 19 received S-1 (80 mg/m2/d; d1-28, q6w or d1-14, q3w), and 4 received other chemotherapy regimens. The clinical records of the patients were reviewed retrospectively. Results: At baseline, S-1 group had a more severe disease status than the mFFX group (performance status of 0: 21% vs. 68%, P = 0.003; median CA19-9 level: 1832 vs. 577 U/mL, P = 0.30). No significant difference in the response rate (S-1, 5.3% vs. mFFX, 9.1%, P = 0.56) or the disease control rate (S-1, 42% vs. mFFX, 36%, P = 0.71) was seen between the two groups. The progression free survival (PFS) (median: S-1 vs. mFFX: 2.7 vs. 2.4 months (m), P = 0.77), the overall survival (OS) from the second-line treatment (median: 6.1 vs. 6.4m, P = 0.87) and the OS from the first-line treatment (median: 10.9 vs. 12.4m, P = 0.77) were not significantly different between the two groups. These results were similar to those observed for MM-398 plus 5FU/LV (PFS, 3.1m; OS, 6.1m) in a pivotal Phase III study (NAPOLI-1). The incidences of peripheral neuropathy (5.3% vs. 32%, P = 0.04), fatigue (11% vs. 50%, P = 0.007), and neutropenia (11% vs. 64%, P = 0.001) were significantly lower in the S-1 group. Conclusions: S-1 was less toxic than mFFX and exerted a similar anti-tumor effect in the present study. S-1 could be a treatment option for patients with mPC refractory to GEM plus nab-PTX.

scholarly journals Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis

Oncotarget ◽  
2018 ◽  
Vol 9 (51) ◽  
pp. 29801-29809 ◽  
Author(s):  
Chiara Citterio ◽  
Michela Baccini ◽  
Elena Orlandi ◽  
Camilla Di Nunzio ◽  
Luigi Cavanna
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Metastatic Pancreatic Cancer ◽  
Second Line ◽  
First Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure

Medicine ◽  
2017 ◽  
Vol 96 (19) ◽  
pp. e6769 ◽  
Author(s):  
Noritoshi Kobayashi ◽  
Takeshi Shimamura ◽  
Motohiko Tokuhisa ◽  
Ayumu Goto ◽  
Itaru Endo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Metastatic Pancreatic Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

2012 ◽  
Vol 69 (6) ◽  
pp. 1641-1645 ◽  
Author(s):  
Alberto Zaniboni ◽  
Enrico Aitini ◽  
Sandro Barni ◽  
Daris Ferrari ◽  
Stefano Cascinu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Pancreatic Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Multicenter Phase ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document